TCMD Tactile Systems Technology (TCMD) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001027838
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
109
13F, latest reported quarter
What the filings say about TCMD
Insiders, 180 days
-$436.7K net sold
2 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$323.2K
2 notices
Tactile Systems Technology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, TACTILE SYSTEMS TECHNOLOGY INC insiders sold a net $436.7K of stock across 58 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 24, 2026.
- The trade is 4.7% of the 232,907 shares held after it.
- No other insider sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dodd Sheri Louise sold about $323.2K of TCMD on Aug 10, 2026; 109 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Feb 24, 2026.
- The trade is 3.6% of the 130,188 shares held after it.
- No other insider sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold about $113.4K of TCMD on May 11, 2026; 109 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 23, 2026.
- The trade is 4.5% of the 243,885 shares held after it.
- 2 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Dodd Sheri Louise sold about $318.1K of TCMD on Feb 24, 2026; 2 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 23, 2026.
- The trade is 5.7% of the 134,819 shares held after it.
- 2 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold about $222.9K of TCMD on Feb 24, 2026; 2 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Feb 23, 2026.
- The trade is 7.6% of the 82,581 shares held after it.
- 2 other insiders sold within 30 days.
- 109 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr. VP Mktg & Clinical Affairs Burns Kristie sold about $180.8K of TCMD on Feb 24, 2026; 2 other insiders sold within 30 days and 109 funds added in the latest 13F quarter.58 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$436.7K over 180 days
-$323.2K over 90 days
below 56% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
109 funds bought in last quarter
more than 65% of Medical Devices
Revenue
+12.5% year over year
more than 55% of Medical Devices
Margin
5.8% net margin
more than 74% of Medical Devices
Buybacks
$6.4M repurchased, FY to 2026-06-30
below 73% of Medical Devices
Short interest
13.8% of the float short (float per yahoo 2026-10-26) · 9.8 days to cover · settled 2026-09-30
more than 93% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TCMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+56.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TCMD: institutional holders (13F)
13F holdings, latest reported quarter
1,905,086 sh
$56.7M
1,576,940 sh
$47.0M
1,092,193 sh
$32.5M
979,340 sh
$29.2M
970,246 sh
$28.9M
Congress trades in TCMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TCMD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
William W Burke
Filed 2026-08-20
-
Dodd Sheri Louise
Filed 2026-08-10
$323.2K
TCMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Paradigm Value Fund
$893.4K position · as of 2026-06-30
1.6%
FULLERTHALER BEHAVIORAL MICRO-CAP EQUITY FUND
$422.9K position · as of 2026-06-30
1.4%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.7M position · as of 2026-06-30
1.1%
Cambria Micro and SmallCap Shareholder Yield ETF
$331.1K position · as of 2026-07-31
1.0%
Janus Henderson Small Cap Value Fund
$11.8M position · as of 2026-06-30
0.9%
Cambria Value and Momentum ETF
$1.0M position · as of 2026-07-31
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $436.7K sold by insiders over 180 days, 109 funds added last quarter, $323.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TCMD financials
Revenue growth
+12.5%
XBRL, annual
Net margin
5.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$350.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TCMD
| FY Dec 2025 | $329.5M |
| FY Dec 2024 | $293.0M |
| FY Dec 2023 | $274.4M |
| FY Dec 2022 | $246.8M |
| FY Dec 2021 | $208.1M |
| Jun 2026 | $85.7M |
| Mar 2026 | $75.3M |
| Dec 2025 | $103.6M |
| Sep 2025 | $85.8M |
| Jun 2025 | $78.9M |
| Mar 2025 | $61.3M |
| Dec 2024 | $85.6M |
| Sep 2024 | $73.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+7.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TCMD
| FY Dec 2025 | +5.8% |
| FY Dec 2024 | +5.8% |
| FY Dec 2023 | +10.4% |
| FY Dec 2022 | -7.2% |
| FY Dec 2021 | -5.7% |
| Jun 2026 | +9.1% |
| Mar 2026 | -2.3% |
| Dec 2025 | +10.3% |
| Sep 2025 | +9.6% |
| Jun 2025 | +4.1% |
| Mar 2025 | -4.9% |
| Dec 2024 | +11.4% |
| Sep 2024 | +7.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$26.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TCMD
| FY Dec 2025 | $40.4M |
| FY Dec 2024 | $38.3M |
| FY Dec 2023 | $33.5M |
| FY Dec 2022 | $3.4M |
| FY Dec 2021 | $528.0K |
| Jun 2026 | $2.0M |
| Mar 2026 | -$1.2M |
| Dec 2025 | $16.8M |
| Sep 2025 | $9.2M |
| Jun 2025 | $14.4M |
| Mar 2025 | $38.0K |
| Dec 2024 | $15.9M |
| Sep 2024 | $9.3M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity TCMD
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.12x |
| FY Dec 2023 | 0.09x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.14x |
| Mar 2025 | 0.13x |
| Dec 2024 | 0.12x |
| Sep 2024 | 0.13x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt TCMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | 1.51x |
| FY Dec 2023 | 2.13x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 1.55x |
| Mar 2025 | 1.49x |
| Dec 2024 | 1.51x |
| Sep 2024 | 1.58x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+11.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TCMD
| FY Dec 2025 | +8.8% |
| FY Dec 2024 | +8.3% |
| FY Dec 2023 | +18.1% |
| FY Dec 2022 | -14.3% |
| FY Dec 2021 | -9.3% |
| Jun 2026 | +11.9% |
| Mar 2026 | +9.6% |
| Dec 2025 | +8.8% |
| Sep 2025 | +8.8% |
| Jun 2025 | +7.6% |
| Mar 2025 | +8.1% |
| Dec 2024 | +8.3% |
| Sep 2024 | +7.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TCMD
| FY Dec 2025 | +6.7% |
| FY Dec 2024 | +5.9% |
| FY Dec 2023 | +10.6% |
| FY Dec 2022 | -7.2% |
| FY Dec 2021 | -5.6% |
| Jun 2026 | +9.0% |
| Mar 2026 | +7.3% |
| Dec 2025 | +6.7% |
| Sep 2025 | +6.6% |
| Jun 2025 | +5.5% |
| Mar 2025 | +5.9% |
| Dec 2024 | +5.9% |
| Sep 2024 | +5.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+17.4%
operating income after a 33.4% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital TCMD
| FY Dec 2025 | +13.8% |
| FY Dec 2024 | +10.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +17.4% |
| Mar 2026 | +14.3% |
| Dec 2025 | +13.8% |
| Sep 2025 | +12.7% |
| Jun 2025 | +9.4% |
| Mar 2025 | +9.7% |
| Dec 2024 | +10.4% |
| Sep 2024 | +10.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TCMD
| FY Dec 2025 | +11.9% |
| FY Dec 2024 | +8.9% |
| FY Dec 2023 | +8.4% |
| FY Dec 2022 | -6.4% |
| FY Dec 2021 | -1.0% |
| Jun 2026 | +14.8% |
| Mar 2026 | +13.4% |
| Dec 2025 | +11.9% |
| Sep 2025 | +9.8% |
| Jun 2025 | +7.9% |
| Mar 2025 | +8.5% |
| Dec 2024 | +8.9% |
| Sep 2024 | +8.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
21.66x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing TCMD
| FY Dec 2025 | 34.94x |
| FY Dec 2024 | 24.47x |
| FY Dec 2023 | 11.92x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 27.57x |
| Mar 2026 | 29.69x |
| Dec 2025 | 34.94x |
| Sep 2025 | 17.97x |
| Jun 2025 | 16.35x |
| Mar 2025 | 20.03x |
| Dec 2024 | 24.47x |
| Sep 2024 | 22.48x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$460.0M
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value TCMD
| FY Dec 2025 | $564.3M |
| FY Dec 2024 | $343.7M |
| FY Dec 2023 | $291.8M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $601.9M |
| Mar 2026 | $511.3M |
| Dec 2025 | $564.3M |
| Sep 2025 | $242.6M |
| Jun 2025 | $181.2M |
| Mar 2025 | $255.2M |
| Dec 2024 | $343.7M |
| Sep 2024 | $295.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield TCMD
| FY Dec 2025 | +6.2% |
| FY Dec 2024 | +9.3% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | +1.5% |
| FY Dec 2021 | +0.1% |
| Jun 2026 | +4.0% |
| Mar 2026 | +6.7% |
| Dec 2025 | +6.2% |
| Sep 2025 | +12.8% |
| Jun 2025 | +16.8% |
| Mar 2025 | +12.1% |
| Dec 2024 | +9.3% |
| Sep 2024 | +11.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.29x
P/E over trailing EPS growth of 74%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing TCMD
| FY Dec 2025 | 1.88x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.37x |
| Mar 2026 | 0.89x |
| Dec 2025 | 1.88x |
| Sep 2025 | 0.97x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2023-12 | |
|---|---|---|---|---|
| Revenue | $329.5M | $293.0M | $274.4M | n/a |
| Gross profit | $250.1M | $216.7M | $195.1M | n/a |
| Operating income | $29.3M | $22.2M | $18.0M | n/a |
| Net income | $19.1M | $17.0M | $28.5M | n/a |
| EPS (diluted) | 0.82 | 0.70 | 1.23 | n/a |
| Operating cash flow | $42.8M | $40.7M | $35.9M | n/a |
| Cash | $83.4M | $94.4M | $61.0M | n/a |
| Long-term debt | $0 | n/a | n/a | $16.8M |
| Buybacks | $26.6M | $3.5M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
TCMD Stock Sonar score 6/7 axes
Find similar shapesCompareTCMD ranks highest on financial health (99th percentile) and profitability (82nd), and lowest on insider conviction (22nd), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TCMD filings, in plain words
Are Tactile Systems Technology insiders buying or selling TCMD?
In the 180 days to 2026-10-28, Tactile Systems Technology insiders were net sellers, a net $436.7K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of TCMD?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $323.2K of stock; the latest, by William W Burke, was filed 2026-08-20.
Read the full summary
In the 180 days to 2026-10-28, Tactile Systems Technology insiders were net sellers of TCMD, a net $436.7K across purchases and sales reported on Form 4 by 2 sellers. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $323.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
